Vera Therapeutics, Inc. (VERA)
| Previous close | 43.44 |
| Open | 43.65 |
| Bid | 44.49 x 100 |
| Ask | 44.84 x 100 |
| Day's range | 42.75 - 44.71 |
| 52-week range | 7.10 - 50.78 |
| Volume | |
| Avg. volume | 1,065,293 |
| Market cap | 2.434B |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.25 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 48.88 |
Simply Wall St.Vera Therapeutics, Inc.'s (NASDAQ:VERA) high institutional ownership speaks for itself as stock continues to impress, up 5.0% over last week
Key Insights Significantly high institutional ownership implies Vera Therapeutics' stock price is sensitive to their...
GuruFocus.comInsider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...
Vera Therapeutics Inc (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, has reported an insider sale according to a recent SEC filing.
- Yahoo Finance Video
Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal
Vertex Pharmaceuticals (VRTX) is set to acquire Alpine Immune Sciences (APLN) for $4.9 billion in cash, gaining access to Alpine's treatments for kidney disease. The deal from Vertex values Alpine's stock at $65 a share, which is a nearly 67% premium from the stock's close on Tuesday. Yahoo Finance Anchors Josh Lipton and Julie Hyman discuss the trend of "pipeline in a product" deals. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Nicholas Jacobino
